Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by princeofcuton Apr 27, 2015 8:26am

176 Views

Post# 23666510

RE:RE:RE:RE:Chines deal secured....naysayers proved wrong yet again :)

GV, why would you be so foolish as to believe much of what DM states... i told you what was coming down the pike...40% the anaconda has now shown its head, mid-2017 is crunch time and IMO when RVX gets taken from retailers, DM will either get a great golden handshake or a nice juicy position with NEWCO...you heard it from me

Bullboard Posts

Cybin launches new program phase to treat Major Depressive Disorder